Diabetes treatment is constantly progressing, with new therapeutic options appearing to improve patient outcomes. Recent studies have focused on GLP-1 and GIP receptor agonists, a class of drugs that mimic the actions of naturally occurring hormones involved in bloodlevel regulation. These novel agents demonstrate substantial potential in improving

Retaglutide and tirzepatide represent a novel class of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are o